89bio
ETNB
ETNB was delisted on the 29th of October, 2025.
38 hedge funds and large institutions have $215M invested in 89bio in 2020 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 14 increasing their positions, 6 reducing their positions, and 3 closing their positions.
267% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 3
133% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 6
27% more funds holding
Funds holding: 30 → 38 (+8)
0.46% less ownership
Funds ownership: 77.6% → 77.13% (-0.46%)
20% less capital invested
Capital invested by funds: $270M → $215M (-$55.3M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$5.47M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.01M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
+$1.05M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$931K |
| 5 |
Morgan Stanley
New York
|
+$779K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$16.1M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
-$1.1M |
| 3 |
Bank of New York Mellon
New York
|
-$246K |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$170K |
| 5 |
BlackRock
New York
|
-$91.7K |
ETNB Hedge Fund Activity: Q2 2020 in Review
38 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in 89bio (ETNB) for Q2 2020, worth a combined $215M — down 20% from $270M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ETNB positions and 3 closed out — a net gain of 8 holders — while 14 added to existing stakes and 6 trimmed.
The largest buyer was Eventide Asset Management, adding an estimated $5.47M. The largest seller was VR Adviser, cutting an estimated $16.1M.
- 38 institutional investors held 89bio (ETNB) as of Q2 2020, up from 30 in Q1 2020.
- Funds reported $215M of 89bio stock for Q2 2020, down 20% quarter-over-quarter.
- 11 funds opened new 89bio positions in Q2 2020 and 3 closed out, a net change of +8 holders.
- The largest 89bio buyer in Q2 2020 was Eventide Asset Management, an estimated $5.47M added.
- The largest 89bio seller in Q2 2020 was VR Adviser, an estimated $16.1M sold.
Based on aggregated 13F filings for Q2 2020.